Coherus Biosciences Inc (NASDAQ:CHRS) shares, rose in value, with the stock price down by -1.90% to the previous day’s close as strong demand from buyers drove the stock to $1.03.
Actively observing the price movement in the last trading, the stock closed the session at $1.05. Referring to stock’s 52-week performance, its high was $2.64, and the low was $0.66. On the whole, CHRS has fluctuated by -7.21% over the past month.
With the market capitalization of Coherus Biosciences Inc currently standing at about $119.36 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CHRS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CHRS currently trading nearly -7.56% and -19.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.18, while the 7-day volatility ratio is showing 8.78% which for the 30-day chart, stands at 7.56%. Furthermore, Coherus Biosciences Inc (CHRS)’s beta value is 0.91, and its average true range (ATR) is 0.10.
A comparison of Coherus Biosciences Inc (CHRS) with its peers suggests the former has fared considerably weaker in the market. CHRS showed an intraday change of -1.90% in last session, and over the past year, it shrunk by -57.26%%. In comparison, Affimed N.V. (AFMD) has moved higher at 5.42%% on the day and was down -81.93% over the past 12 months. On the other hand, the price of Repligen Corp. (RGEN) has risen 1.85%% on the day. The stock, however, is off -19.20% from where it was a year ago.
Data on historical trading for Coherus Biosciences Inc (NASDAQ:CHRS) indicates that the trading volumes over the past 3 months, they’ve averaged 2.31 million. According to company’s latest data on outstanding shares, there are 115.21 million shares outstanding.
Nearly 3.97% of Coherus Biosciences Inc’s shares belong to company insiders and institutional investors own 55.15% of the company’s shares. The stock has fallen by -25.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CHRS stock heading into the next quarter.
